{"protocolSection":{"identificationModule":{"nctId":"NCT02145689","orgStudyIdInfo":{"id":"191622-129"},"secondaryIdInfos":[{"id":"2013-002327-42","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Allergan","class":"INDUSTRY"},"briefTitle":"Long-Term Study of OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity"},"statusModule":{"statusVerifiedDate":"2014-08","overallStatus":"WITHDRAWN","whyStopped":"The study was withdrawn prior to enrollment due to corporate decision.","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2014-08"},"primaryCompletionDateStruct":{"date":"2017-05","type":"ESTIMATED"},"completionDateStruct":{"date":"2017-05","type":"ESTIMATED"},"studyFirstSubmitDate":"2014-05-21","studyFirstSubmitQcDate":"2014-05-21","studyFirstPostDateStruct":{"date":"2014-05-23","type":"ESTIMATED"},"lastUpdateSubmitDate":"2014-08-12","lastUpdatePostDateStruct":{"date":"2014-08-13","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Allergan","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This is a long-term safety and efficacy study of onabotulinumtoxinA in poststroke patients with upper limb spasticity."},"conditionsModule":{"conditions":["Muscle Spasticity","Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR"]}},"enrollmentInfo":{"count":0,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"onabotulinumtoxinA Dose 1","type":"EXPERIMENTAL","description":"Up to 4 treatments of onabotulinumtoxinA Dose 1 injected into muscles of the study limb on fulfillment of the retreatment criteria.","interventionNames":["Biological: onabotulinumtoxinA"]},{"label":"onabotulinumtoxinA Dose 2","type":"EXPERIMENTAL","description":"Up to 4 treatments of onabotulinumtoxinA Dose 2 injected into muscles of the study limb on fulfillment of the retreatment criteria.","interventionNames":["Biological: onabotulinumtoxinA"]}],"interventions":[{"type":"BIOLOGICAL","name":"onabotulinumtoxinA","description":"Up to 4 treatments of onabotulinumtoxinA injected into muscles of the study limb on fulfillment of the retreatment criteria.","armGroupLabels":["onabotulinumtoxinA Dose 1","onabotulinumtoxinA Dose 2"],"otherNames":["BOTOXÂ®","botulinum toxin type A"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change from Baseline in the Modified Ashworth Scale-Bohannon (MAS-B) Score of Treated Muscle Groups Using a 6-Point Scale","timeFrame":"Baseline, Up to 60 Weeks"}],"secondaryOutcomes":[{"measure":"Clinical Global Impression (CGI) of Overall Change by Physician Compared to Baseline Using a 9-Point Scale","timeFrame":"Baseline, Up to 60 Weeks"},{"measure":"Change from Baseline in Pain on an 11-Point Scale","timeFrame":"Baseline, Up to 60 Weeks"},{"measure":"Change from Baseline in the 19-Item Spasticity Impact Assessment-Upper Limb (SIA-UL) Score","timeFrame":"Baseline, Up to 60 Weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* For patients entering from the 191622-127 study, successful completion of study 191622-127\n* For patients entering directly into study 191622-129, upper limb spasticity in the elbow and shoulder due to stroke, with the most recent stroke at least 3 months ago\n\nExclusion Criteria:\n\n* Spasticity in the non-study upper limb that requires treatment\n* Presence of fixed contractures in of the study muscles in elbow or shoulder\n* Profound atrophy of muscles to be injected\n* Previous surgical intervention, nerve block, or muscle block for the treatment of spasticity in the study limb in the last 12 months\n* Injection of corticosteroids or anesthetics, use of casting or dynamic splinting or constraint-induced movement therapy (CIMT) for the study limb within 3 months\n* Ultrasound therapy, electrical stimulation, or acupuncture in the study limb within 1 month\n* Condition other than stroke contributing to upper limb spasticity\n* Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, and/or amyotrophic lateral sclerosis","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Director","affiliation":"Allergan","role":"STUDY_DIRECTOR"}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14","removedCountries":["United States"]},"conditionBrowseModule":{"meshes":[{"id":"D000009128","term":"Muscle Spasticity"}],"ancestors":[{"id":"D000009135","term":"Muscular Diseases"},{"id":"D000009140","term":"Musculoskeletal Diseases"},{"id":"D000009122","term":"Muscle Hypertonia"},{"id":"D000020879","term":"Neuromuscular Manifestations"},{"id":"D000009461","term":"Neurologic Manifestations"},{"id":"D000009422","term":"Nervous System Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M11775","name":"Muscle Spasticity","asFound":"Muscle Spasticity","relevance":"HIGH"},{"id":"M11782","name":"Muscular Diseases","relevance":"LOW"},{"id":"M11787","name":"Musculoskeletal Diseases","relevance":"LOW"},{"id":"M11769","name":"Muscle Hypertonia","relevance":"LOW"},{"id":"M22309","name":"Neuromuscular Manifestations","relevance":"LOW"},{"id":"M12094","name":"Neurologic Manifestations","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC05","name":"Musculoskeletal Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000001905","term":"Botulinum Toxins"},{"id":"D000019274","term":"Botulinum Toxins, Type A"},{"id":"C000542869","term":"abobotulinumtoxinA"}],"ancestors":[{"id":"D000065087","term":"Acetylcholine Release Inhibitors"},{"id":"D000049990","term":"Membrane Transport Modulators"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000018678","term":"Cholinergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000009465","term":"Neuromuscular Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"}],"browseLeaves":[{"id":"M4873","name":"Botulinum Toxins","asFound":"250","relevance":"HIGH"},{"id":"M250157","name":"abobotulinumtoxinA","asFound":"Maintenance therapy","relevance":"HIGH"},{"id":"M20947","name":"Botulinum Toxins, Type A","asFound":"Maintenance therapy","relevance":"HIGH"},{"id":"M3163","name":"Acetylcholine","relevance":"LOW"},{"id":"M20448","name":"Cholinergic Agents","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"VaDiAg","name":"Vasodilator Agents"}]}},"hasResults":false}